HBO After Thrombectomy for AIS With LVO

Inclusion Criteria: 1. Age 18\~80 years; 2. Clinically diagnosed as acute large vessel occlusive ischemic stroke, suitable for and received endovascular treatment according to current clinical guidelines; 3. The onset of stroke or the last normal time to the time of endovascular treatment ≤ 24 hours; 4. Pre-stroke mRS score of 0 or 1; 5. Baseline NIHSS score before endovascular treatment ≥ 6 points in the anterior circulation or ≥10 points in the posterior circulation; 6. CTA, MRA, or DSA angiography before endovascular treatment confirmed occlusion of large vessels (internal carotid artery, middle cerebral artery M1 segment, basilar artery), consistent with symptoms and signs; 7. The corresponding anterior circulation ASPECTS score or posterior circulation pc-ASPECTS score ≥ 6 points; 8. The pontine midbrain index (PMI) of patients with acute basilar artery occlusion ≤3; 9. Patients or their family members sign the informed consent form. Exclusion Criteria: 1. Patients with extensive bleeding or severe increase in infarct area, midline displacement (\>0.5cm), etc. during endovascular treatment, who plan to undergo bone valve decompression or ventricular drainage; 2. Known bleeding risk factors, including coagulation factor deficiency, or receiving anticoagulant therapy, INR\>3.0 or APTT \> 3 times normal or platelet count less than 50×10⁹/L; 3. Severe hepatic or renal dysfunction (severe hepatic dysfunction refers to ALT or AST \> 3 times the upper limit of the normal range, severe renal dysfunction refers to serum creatinine Cr \>1.5 times the upper limit of the normal range); 4. Females of pregnancy, or positive pregnancy test prior to randomization; 5. Severe persistent and medication-uncontrollable hypertension (systolic blood \> 185 mmHg or diastolic blood \> 110 mmHg) 6. Baseline blood glucose of \<50 mg/dL (2.78 mmol/L) or \>400 mg/dL (22.20 mmol/L); 7. The oxygen required to maintain 95% of peripheral arterial oxygen saturation (SaO2) under the current medium-term management guidelines \> 3L/min; 8. End-stage disease other than the nervous system, life expectancy \< 90 days; 9. Participating in other drug or medical device clinical trials; 10. CT or MR suggests intracranial tumors (other than meningiomas) or other high-risk intracranial vascular malformations; 11. Patients with anemia, polycythemia or other conditions requiring urgent oxygen; 12. Unable to cooperate with hyperbaric oxygen therapy, or have other diseases that are not suitable for hyperbaric oxygen therapy (such as active/chronic obstructive pulmonary disease, acute respiratory distress syndrome, tension pneumothorax, tension pneumocephalus, etc.).